» Articles » PMID: 38873669

Macrophage Polarisation and Inflammatory Mechanisms in Atherosclerosis: Implications for Prevention and Treatment

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Jun 14
PMID 38873669
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis is a chronic inflammatory disease characterised by plaque accumulation in the arteries. Macrophages are immune cells that are crucial in the development of atherosclerosis. Macrophages can adopt different phenotypes, with the M1 phenotype promoting inflammation while the M2 phenotype counteracting it. This review focuses on the factors that drive the polarisation of M1 macrophages towards a pro-inflammatory phenotype during AS. Additionally, we explored metabolic reprogramming mechanisms and cytokines secretion by M1 macrophages. Hyperlipidaemia is widely recognised as a major risk factor for atherosclerosis. Modified lipoproteins released in the presence of hyperlipidaemia can trigger the release of cytokines and recruit circulating monocytes, which adhere to the damaged endothelium and differentiate into macrophages. Macrophages engulf lipids, leading to the formation of foam cells. As atherosclerosis progresses, foam cells become the necrotic core within the atherosclerotic plaques, destabilising them and triggering ischaemic disease. Furthermore, we discuss recent research focusing on targeting macrophages or inflammatory pathways for preventive or therapeutic purposes. These include statins, PCSK9 inhibitors, and promising nanotargeted drugs. These new developments hold the potential for the prevention and treatment of atherosclerosis and its related complications.

Citing Articles

Deciphering Oxidative Stress in Cardiovascular Disease Progression: A Blueprint for Mechanistic Understanding and Therapeutic Innovation.

Zhang Z, Guo J Antioxidants (Basel). 2025; 14(1).

PMID: 39857372 PMC: 11759168. DOI: 10.3390/antiox14010038.


Protocol to generate a 3D atherogenesis-on-chip model for studying endothelial-macrophage crosstalk in atherogenesis.

Hanford K, Dzobo K, Versloot M, Peter J, Kroon J STAR Protoc. 2025; 6(1):103559.

PMID: 39799579 PMC: 11773240. DOI: 10.1016/j.xpro.2024.103559.


Common ground on immune infiltration landscape and diagnostic biomarkers in diabetes-complicated atherosclerosis: an integrated bioinformatics analysis.

Qi Y, Zhang Y, Guan S, Liu L, Wang H, Chen Y Front Endocrinol (Lausanne). 2024; 15:1381229.

PMID: 39145311 PMC: 11323117. DOI: 10.3389/fendo.2024.1381229.

References
1.
Serhan C . Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014; 510(7503):92-101. PMC: 4263681. DOI: 10.1038/nature13479. View

2.
Gautier E, Huby T, Witztum J, Ouzilleau B, Miller E, Saint-Charles F . Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation. 2009; 119(13):1795-804. DOI: 10.1161/CIRCULATIONAHA.108.806158. View

3.
Lopategi A, Flores-Costa R, Rius B, Lopez-Vicario C, Alcaraz-Quiles J, Titos E . Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome. J Leukoc Biol. 2018; 105(1):25-36. DOI: 10.1002/JLB.3HI0517-206RR. View

4.
ONeill L . A broken krebs cycle in macrophages. Immunity. 2015; 42(3):393-4. DOI: 10.1016/j.immuni.2015.02.017. View

5.
Barrett T . Macrophages in Atherosclerosis Regression. Arterioscler Thromb Vasc Biol. 2019; 40(1):20-33. PMC: 6946104. DOI: 10.1161/ATVBAHA.119.312802. View